<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>17020716</identifier>
<setSpec>0212-6567</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Hospital Guardiola, Inmaculada</dc:author>
<dc:author>Raga Luria, Xavier</dc:author>
<dc:author>Ochoa Gondar, Olga</dc:author>
<dc:author>Salsench Serrano, Elisabet</dc:author>
<dc:author>Vila Córcoles, Angel</dc:author>
<dc:author>Vilanova Navarro, Angels</dc:author>
<dc:description xml:lang="en">OBJECTIVE To assess the effectiveness of 23-valent polysaccharide vaccine in preventing severe pneumococcal infections in adults over 50 years old. DESIGN Case-control study. SETTING Primary Health Care Service, Tarragona, Spain. PATIENTS A total of 270 patients &gt;50 with severe pneumococcal disease (invasive pneumococcal disease and non-bacteraemic pneumococcal pneumonia) and 540 control patients randomized from the primary care Centres of the case patients. Case and control patients will be matched for age, sex, family physician, and level of risk for pneumonia. MAIN MEASUREMENTS Odds ratio (OR) will be used to measure the vaccine effect. Multivariate logistical regression, adjusted for age, sex, and comorbidity, will be conducted. Vaccine effectiveness (VE) will be calculated by the formula, VE = 1-OR. Vaccine effectiveness will be distinguished for the various age groups and at each risk stratum. It will also be estimated by means of indirect cohort analysis, taking as cases the infection caused by vaccine serotypes and as controls infection caused by non-vaccine serotype. DISCUSSION The study will give an answer in terms of effectiveness of the vaccine for several age and risk strata. It will contribute to taking a decision regarding the controversial question of the systematic indication, or otherwise, of this vaccine for the elderly.</dc:description>
<dc:type>Comparative Study</dc:type>
<dc:language>es</dc:language>
<dc:date>2006 Sep 30 </dc:date>
<dc:title xml:lang="es">Estudio EVAN-50: efectividad de la vacuna antineumocócica polisacárida en la prevención de infecciones neumocócicas en población mayor de 50 años.</dc:title>
<dc:title xml:lang="en">[EVAN-50 study: Effectiveness of polysaccharide pneumococcus vaccine in preventing pneumococcal infections in the over-50 population].</dc:title>
<dc:publisher>Atencion primaria</dc:publisher>
</metadata>
</record>
</pubmed-document>
